Back to discover
Drug

Cariprazine hydrochloride

Approved · EMA

Also known as Vraylar, cariprazine (as hydrochloride), cariprazine HCl.

RxNorm1721073
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: Reagila (EMA)

Regulatory2017-07-13EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Cariprazine hydrochloride
Aliases & brands
Vraylarcariprazine (as hydrochloride)cariprazine HCl
RxNorm CUI
1721073
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2017-07-13
Latest approval
2017-07-13
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2017-07-13Approval
Approval: Reagila (EMA)

Indication: Reagila is indicated for the treatment of schizophrenia in adult patients.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.